The interactions between the effects of the sympathetic nervous system (SNS) and angiotensin II (ANG II) on vascular extracellular matrix (ECM) synthesis were determined in rats. The mRNA and protein content of collagen I, collagen III and elastin in the abdominal aorta (AA) and femoral artery (FA) was investigated in Wistar-Kyoto rats treated for 5 weeks with guanethidine, a sympathoplegic, losartan, an ANG II AT1 receptor (AT1R) blocker, or both. The effects of noradrenaline (NE) and ANG II on collagen III and elastin mRNA, and the receptor involved, were tested in cultured vascular smooth muscle cells (VSMCs) in vitro. Guanethidine increased collagen types I and III and decreased elastin, while losartan had an opposite effect, although without effect on collagen III. The combination of treatments abrogated changes induced by simple treatment with collagen I and elastin, but increased collagen III mRNA in AA and not in FA. NE stimulated collagen III mRNA via b receptors and elastin via a1 and a2 receptors. ANG II stimulated collagen III but inhibited elastin mRNA via AT1R. Overall, SNS and ANG II exert opposite and antagonistic effects on major components of ECM in the vascular wall. This may be of relevance for the choice of a therapeutic strategy in vascular diseases.
Introduction
Extracellular matrix (ECM) is an essential component of pluricellular organisms, since it is the substratum secreted by cells to 'condition' their medium and the shape of the organ and organism. In the arterial wall, the ECM determines both structural properties such as shape and resistance and functional properties such as elasticity and blood flow. 1 The ECM in the vascular wall is mostly composed of collagen types I and III 2 and elastin embedded in mucopolysaccharides and adhesion molecules.
From a functional point of view, the ECM composition and turnover are regulated by genetic factors as well as blood pressure or shear stress, blood flow and neuroendocrine factors such as the renin-angiotensin system (RAS) and the sympathetic nervous system (SNS). [3] [4] [5] The effect of the SNS, and mostly of b-adrenergic stimulation, on ECM has been investigated in depth in the heart. 6 However, much less is known about the role of the SNS in the regulation of ECM production in the arterial wall and vascular smooth muscle cells (VSMCs). Most published data indicate an increase of total collagen and a decrease in the amount of elastin in the arterial wall after sympathectomy. 7, 8 On the other hand, the mechanisms involved in angiotensin II (ANG II) induced vascular remodelling have been investigated in much more detail. ANG II directly exerts its effects on VSMCs through angiotensin II type 1 receptors (AT1R) by activation of phospholipase C. 9, 10 The activation of AT1R by ANG II induces growth and cell migration of VSMCs and modulates collagen synthesis by fibroblasts. 11 Interactions between SNS and RAS have been investigated in the heart. 12, 13 It was shown not only that ANG II could increase sympathetic outflow but also that it was required for isoproterenol induced heart hypertrophy. In the peripheral vessels, neuro-humoral interactions between the SNS and the RAS have been described. AT1R have been located on presynaptic terminals of perivascular sympathetic fibres and have been shown to activate and amplify noradrenaline release acting on blood vessels. [14] [15] [16] The AT1R blockade reduces NE release 14 and enhances its uptake by SNS terminal axons. 17 However, very few studies have described the interactions between the two systems in the vascular bed, 18, 19 most often in pathological models.
The aim of this study was to clarify the interactions between the SNS and AT1R mediated ANG II effects on ECM production in the rat vasculature, centred on VSMCs. For this purpose, blockade of the SNS with guanethidine and of AT1R with losartan was performed alone or in combination to determine their respective contributions to ECM synthesis in the rat vessels. Primary cultures of VSMCs were used to identify the direct effects and the receptors involved.
Materials and methods

Animals
The animal protocols used for this study were approved by the University Animal Care and Use Committee of University of Claude Bernard, Lyon 1, France and were in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Male Wistar-Kyoto rats (n = 32) were divided equally into four groups: a guanethidine treated group (GUA), a losartan treated group (LOS), a double treatment group (GUA+LOS) and a control group (CTRL). Rats were treated as previously described 13 with guanethidine sulfate (50 mg/kg intraperitoneal injection, 5 days/week for 5 weeks) (Sigma, St Louis, MO, USA) for a sympathectomy. Losartan (20 mg/kg/ day) was administered in drinking water for 5 weeks to block AT1R. The double treatment group received both guanethidine and losartan as described above for 5 weeks. The CTRL group received injections of saline for the same time period.
At the end of the treatment period, rats were deeply anaesthetised with pentobarbital (50 mg/kg i.p.). AA and FA were removed, carefully dissected from surrounding fat, immediately frozen in liquid nitrogen, and stored at −80°C.
Blood pressure measurement
Systolic blood pressure (SBP) was measured weekly during the 5 weeks of treatment via a tail-cuff method. 20 
Cell culture
VSMCs were obtained from AA samples with the explant technique (n = 6). Briefly, a strip of AA, carefully dissected by removing the adventitia, was cut into small fragments, which were placed in 25 cm² culture dishes in Dulbecco's Modified Eagle's Medium (DMEM) culture medium supplemented with fetal calf serum 10% (Promocell), glutamine 4.5 mM and antibiotic (streptomycin 0.1 g/l and penicillin 100 U/ml), maintained at 37°C and 5% CO 2 . Experiments were performed on cells from passages 2 to 4. VSMCs were checked by immunostaining of actin with anti-a-smooth muscle actin antibody (DAKO). [21] [22] [23] For the experiments, 100,000 cells were seeded in 12-well plates in their usual medium for at least 1 day. Twenty-four hours before the experiments, culture medium was changed to a basal VSMCs medium without fetal calf serum. On the day of the experiments, culture medium was replaced and the test substances were added at appropriate concentrations for 24 h as follows: noradrenaline (NE) (Fluka): 0, 10 nM, 100 nM or 1 µM with or without one of the specific adrenoreceptor antagonists (Sigma) b (50 µM propranolol), a1 (100 nM prazosin) and a2 (10 µM yohimbine); ANG II: 0, 25 pM, 100 nM or 1 µM with or without 10 µM of losartan (Sigma), the specific AT1R antagonist.
Total RNA extraction and real-time RT-PCR analysis
RNA was extracted from AA, FA and cultured aortic VSMCs using Trizol Reagent (Invitrogen, Carlsbad, CA) and treated with DNase (Deoxyribonuclease I, Amplification Grade, Invitrogen). The integrity of the purified RNA was verified by agarose gel electrophoresis followed by ethidium bromide staining. After DNase treatment, 5 µg of total RNA was reverse-transcripted with superscript II transcriptase (Invitrogen, France) using random hexamers as primers (pdN6; Amersham Biosciences, Piscataway, NJ). Real-time Reversetranscriptase polymerase chain reaction (RT-PCR) for selected gene transcripts was performed using the resulting cDNA as template with a MyiQ thermal cycler (Bio-Rad Laboratories, Hercules, CA) with iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) Values are means ± SD. ** p < 0.01, *** p < 0.001 versus CTRL, ττ p < 0.01 versus sympathectomy group, § § p < 0.01 versus losartan treated group. CTRL: control, GUA: sympathectomy group, GUA+LOS: double treatment group, LOS: losartan treated group. Laboratories). Expression levels obtained from the standard curves were normalised against 18S rRNA.
Protein extraction and western blotting
Protein extraction and western blotting were performed as previously described. 13 We used mouse monoclonal IgG antibodies specific for collagen types I and III or elastin (1:2000) and b-actin (1:5000). All anti bodies were from Sigma. Immunoreactivity of proteins was visualised by chemiluminescent detection (ECL, Amersham, Bucking hamshire, UK). Pre-stained molecular weight markers (Sigma) were used to assess and to check the separation and transfer of the appropriate protein.
Visualised proteins were scanned and optical density was measured with Scion image software. Values were normalised to b-actin assessed on the same membranes after stripping off the first reaction.
Statistical analysis
Statistical comparisons between treated and control groups were performed using ANOVA test. Subsequent pair-wise comparisons were performed with the HSD Tukey test using Statistica software (statsoft, France). Results are expressed as mean ± standard error of the mean (SEM). p < 0.05 is taken as a significant probability and n values indicate the number of replicates.
Results
Control animals and those treated with losartan alone did not show anomalous behaviour. As expected, animals treated with guanethidine displayed ptosis as a consequence of chemical sympathectomy. 24 The body weights were similar in the four groups at the end of the treatment period ( Table 2) . SBP was similar after losartan and guanethdine treatment, and remain significantly lower then control animals. Those receiving the double treatment had significantly lower SBP than CTRL, GUA and LOS rats.
In vivo study
Abdominal aorta. Sympathectomy significantly increased mRNA levels of collagen I and collagen III (p < 0.05), while significantly decreasing the amount of elastin mRNA (p < 0.05). Losartan treatment decreased collagen I (p < 0.05), had no effect on collagen III and increased elastin (p < 0.05) versus CTRL. After combined treatment, mRNA levels of collagen I and elastin were still similar to CTRL, while collagen III mRNA was increased (p < 0.05) (Figure 1 A and C).
There was a good correlation between mRNA and protein levels for all studied targets. Sympathectomy significantly enhanced collagen I and collagen III protein amounts (p < 0.05) and reduced elastin protein (p < 0.05). Losartan treatment significantly decreased collagen I and enhanced elastin (p < 0.05) without affecting the amount of collagen III. Combined treatment significantly enhanced only collagen III protein expression (p < 0.05) (Figure 1 B and D) .
Femoral artery. In control rats, in accordance of differences between conductance and resistance arteries our results indicate that ECM mRNA was more expressed in AA than in FA; thus, amounts of collagen I and collagen III mRNA, respectively, were about 19-fold and two-fold higher and elastin mRNA nine times more abundant in AA than in FA.
Similarly to AA, sympathectomy significantly increases the amounts of collagen I and collagen III mRNA (p < 0.01), while decreasing the amount of elastin (p < 0.05). Losartan treatment decreases collagen I (p < 0.01) and increases elastin (p < 0.01) without affecting collagen III. In the double treatment group, amounts of elastin, collagen I and collagen III mRNA were similar to CTRL (Figure 2 ).
VSMCs stimulation
Basal characteristics of VSMCs. All cells present in culture were immunolabelled for a-smooth muscle actin, demonstrating their nature as VSMCs (data not shown). In basal conditions without fetal calf serum and in the presence of physiological concentrations of insulin and glucose for 24 h, collagen III and elastin mRNA were detected in rat VSMCs.
Effect of NE on ECM gene expression
NE induced a dose dependent increase in collagen III and elastin mRNA levels. The increase was three-fold (p < 0.01 and p < 0.05, respectively) compared with untreated cells at the lowest NE concentration. At the highest doses of NE, elastin mRNA was more amplified than collagen III mRNA, by about eight-fold for elastin and more than five-fold for collagen III.
The effect of NE on mRNA levels for collagen III was abrogated completely by b blockade. NE-induced elastin mRNA expression was completely inhibited by a1 and a2 blockade and partially by b blockade (Figure 3 ).
Effect of ANG II on ECM gene expression
ANG II treatment induced a linear dose dependent stimulation of collagen III mRNA level, while elastin mRNA was similarly reduced (about two-fold; p < 0.05) at the three doses of ANG II (25 pM, 100 nM and 1 µM) ( Figure 4 ). Losartan completely inhibited ANG II-induced changes in expression of collagen III and elastin.
Discussion
In the present study we showed that in vivo a sympathoplegic drug (guanethidine) and an ANG II AT1R antagonist (losartan), while both had similar and additive decreasing effects on blood pressure, had opposite effects on collagen and elastin expression, which antagonised each other when the two drugs were given in combination. These effects were present in both an elastic artery, AA, and a resistance vessel, the FA. In parallel, an in vitro study using primary VSMCs showed that, while all the effects of ANGII were mediated via AT1R, those of NE were mediated mainly by a-adrenoceptors and partially by b-adrenoceptors for elastin and through b-adrenoceptors for collagen III. Moreover, the close parallelism between mRNA and protein levels for the three examined ECM components in the three treated groups indicates that protein changes are directly related to their respective mRNA, and thus that regulation takes place at the transcriptional level.
In this study we assessed interaction between SNS and ANG II through AT1R but not ATR2. Therefore we have not tested AT2R antagonists, since AT1R has been well documented as the main ANG II receptor in several tissues such as vessel wall, heart and adrenal gland. 25 Moreover, AT2R is unequally expressed in tissues like brain, heart and vessels and is only slightly expressed in blood vessels compared with other tissues. Furthermore, in the vascular bed it has been demonstrated that AT2R expression was not constant during embryonic development and in the neonate, whereas the AT1R in aorta is expressed at relatively constant levels from the first embryonic development to the adult stage, 26, 27 and AT2R expression declines rapidly after birth. 28 Thus, previous investigation has shown a higher level of AT2R mRNA expression in the outer medial-adventitial region, which persists after birth in the neonate, but completely disappears at 22 days after birth. 29 As mentioned above, there is much evidence that ANG II acts only through AT1R in aortic cells of adult rats.
Interaction between the SNS and ANG II has been demonstrated by functional studies. Thus ANG II stimulates NE release from the SNS through AT1R expressed in sympathetic fibres coursing the blood vessels (presynaptic receptors) and in VSMCs. 30 The use of a specific antagonist of AT1R lowers NE release 15 and enhances its uptake by SNS terminal axons. 17 Therefore ANG II can act indirectly via SNS. This has been termed the sympathostimulator pathway. 12 Based on the literature, we hypothesise that ANG II acts in two ways to influence the local ECM synthesis: first by acting directly on the vascular wall via AT1R, and second via the sympathostimulator pathway.
To describe the crosslink between the two modes of action of ANG II, we proposed that: 1) sympathectomy induces elimination of SNS and thus ANG II action by the sympathostimulator pathway. In this condition, ANG II remains freely accessible only to AT1R on vessel tissue; 2) the combination of sympathectomy and AT1R blockade with losartan allows the action of ANG II mediated via its AT1R expressed in vessels cells (direct pathway) to be examined; 3) in the losartan treated group, losartan induces blockage of AT1R in both presynaptic sympathetic fibres and vessel tissue. The blockage of AT1R in SNS reduces noradrenaline (NE) release and enhances its uptake. 17 The sympathostimulator pathway (indirect pathway) could be determined by comparison of the three experiments.
ECM is not simply an inert supporting network, but, rather, comprises an active and dynamic structure that has a fundamental role in the regulation of cardiovascular function in normal and pathological conditions. Abnormal synthesis or excessive reduction of ECM leading to cardiovascular diseases has been associated with hypertension, which is under the influence of SNS and ANG II. 31 Type I and III collagens represent the major ECM components. In our study we have investigated the effect of SNS and ANG II on the two collagen types in vivo, but only collagen III was investigated in an in vitro study, for two reasons. First, we found that the two collagen types have approximately the same profiles of changes after all treatments, and to abridge the experimental procedure we chose to work only with collagen III in our in vitro study. Second, it has been established that collagen III is relatively more abundant in tissues subjected to periodic stress, such as the vasculature, and participates in the tridimensional organisation of type I collagen networks, and that only mutations in collagen III are associated with vascular diseases (for review see Arteaga-Solis et al. 32 ).
Paradoxically, while in vivo collagen III mRNA and also collagen I mRNA and protein levels were enhanced by sympathectomy, NE was still a potent stimulator of collagen III expression in isolated cells. These results are in accordance with previous reports. 7, [33] [34] [35] This discrepancy may be related to an in vivo ANG II-induced stimulation response. From our in vivo study, ANG II seems to stimulate directly, via AT1R, the gene expression of collagen I in AA and of both collagen I and III in FA. Along with this hypothesis, in our experimental model, guanethidine, which induces destruction of sympathetic perivascular fibres, 36 most likely also eliminates the interaction of ANG II with sympathetic nerve terminals in the two sympathectomy groups (GUA and GUA+LOS groups). The increased synthesis of collagen seen in the GUA group was abolished or reduced by a combination with AT1R blockade (GUA+LOS group).
Based on our animal experiments, ANG II does not seem to be directly involved in the stimulation of the gene expression of collagen III in AA, since AT1R blockade was unable to reduce this level with or without sympathectomy. It has been reported that the stimulatory effect of ANG II depends on the type of collagen in human VSMCs, collagen V being more stimulated than collagen I and III. 37 The increased collagen III seen in the GUA group is not reduced by AT1R blockade in LOS+GUA. These in vivo results may appear paradoxical when compared with in vitro data showing a strong stimulatory effect of ANG II on collagen III. One explanation is that, in contrast to collagen I, endogenous levels of ANG II induce only a weak stimulation of gene expression of collagen III in large arteries in vivo, and thus AT1R blockade was swamped by other stimulator factors such as endothelin.
Elastin mRNA and protein levels were differentially regulated by losartan and guanethidine, exerting opposite and antagonistic effects. Interestingly, our results suggest that ANG II inhibits directly via AT1R elastin gene expression, since the reduced level of elastin mRNA seen in the GUA group was blunted by AT1R blockage in the GUA+LOS group. SNS stimulates this level, since the stimulatory effect of losartan was reduced when associated with sympathectomy. In accordance with in vivo study, NE enhances elastin mRNA via a1 and a2-adrenergic receptors, and partially also by b-adrenergic receptors. Thus, ANG II may play a double role in elastin mRNA synthesis, by mediating a direct inhibition via AT1R on vascular smooth muscle cells and possibly by an indirect stimulation via potentiation of NE release from the SNS.
Interestingly, we found that NE-induced stimulation of collagen III and elastin expression was mediated differently by a and b-adrenergic receptors. It is, therefore, very likely that collagen and elastin mRNA expression had different intracellular transduction signal pathways, an aspect that warrants further investigation, since no previous reports have discussed this finding in rat aorta under normal conditions. In our study there was no correlation between elastin expression and SBP changes in the three treated groups. Elastin was seen to increase or to reduce when SBP was reduced. However, in the case of collagen expression, the study raises the question of distinction between direct sympathetic and ANG II action on collagen expression and that induced by haemodynamic factors. It has been established that RAS plays an important role in the pathogenesis of vascular hypertrophy and arterial stiffness mainly through ANG II, which is involved in the development of hypertension by increasing the collagen content of the arterial wall, thickening and fibrotic remodelling, resulting in increased thickness and stiffening, 38, 39 and the use of ANG II antagonists provides prevention of the damaging effects of hypertension on the arterial wall. 40 These observations agree with our present data, since we found that losartan treatment diminished blood pressure, which is correlated with the profiles of collagen changes. On the other hand, previous investigations in heart and vessels have advanced some arguments that work against direct involvement of blood pressure in cardiovascular fibrosis. [41] [42] [43] Moreover, studies by Weber and co-workers have shown that myocardial fibrosis is not related to haemodynamic workload, 42 which is closely associated with arterial pressure. 44 ECM proteins are mostly regulated by the activity of a set of proteins such as matrix metalloproteinase (MMP). MMPs constitute a tightly regulated family of zinc dependent endopeptidases that degrade most components of the ECM and basement membrane, and can also function in many other proteolytic processes. 45 The effect of each treatment presented in this study can be related either to imbalance of synthesis or/and to proteolysis by MMPs. In this context, we have tested in previous studies the effect of the three treatments on MMP and ECM expression in heart, 13, 46 and have described the existence of a difference in relative amounts of mRNA and protein levels of ECM, with usually a higher level of protein than mRNA after the same three treatments used in this study. This observation was attributed to the posttranslational regulation of ECM proteins assisted by MMP, since we found that the synthesis and enzymatic activity of MMPs were decreased in the three treated groups.
Accumulation of interstitial collagen contributes to increased arterial stiffness, 47 and its excessive reduction is a structural feature of vascular diseases leading to the fragility and rupture of atheromatous plaque or to the development of aneurysms. 48 Altogether, our results help elucidate the interactions between these two systems in the regulation of vascular ECM production, as shown in Figure 5 . The Figure 5 . Schematic illustration of interaction between effects of SNS and ANG II on ECM expression: collagen I and III and elastin in arterial smooth muscle cells. Black arrows: SNS-mediated action. Grey arrows: ANG II-mediated action, indirectly via SNS or directly via AT1R. The blockage of AT1R reduces the liberation of NE from SNS. When SNS is inhibited, ANG II can stimulate directly via AT1R collagen synthesis, leading to the increase of collagen protein. ANG II seems to stimulate collagen III mRNA moderately, and the blockage of its AT1R remains insufficient to reduce the level of this collagen, perhaps because of other stimulator systems such as endothelin that are activated when activity of SNS is reduced. ANG II exerts antagonistic action on gene expression of elastin, stimulation via SNS and an inhibition directly via AT1R. ANG II: angiotensin II, AT1R: angiotensin II AT1 receptor, ECM: extracellular matrix, NE: noradrenaline, SNS: sympathetic nervous system. inhibition of SNS or ANG II separately has been widely used to reduce cardiovascular mortality and morbidity. Therefore, comparisons have made between the effects of adrenergic antagonists and AT1R antagonists, 49 but there has been less investigation of combined treatments.
In conclusion, the present study allows a comparison between the effect of simple and combined treatments on expression of the major actors on vascular ECM remodelling, and demonstrates opposing effects of ANG II and SNS on ECM synthesis and a compensatory effect of combined treatments on changes of ECM expression induced by simple inhibition of ANG II and SNS, which are widely used in treatment of cardiovascular diseases. Moreover, in our previous study 46 we demonstrated that combined treatment was more efficient than simple treatment for reducing the expression of MMP in heart. The combined treatment may be useful as a new therapeutic approach for better prevention and treatment of cardiovascular disorders, and needs to be investigated in depth.
